

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/665,363	09/19/2000	Y. Tom Tang	789CIP2C	5054
75	590 03/22/2002			
Leslie A Mooi			EXAMINER	
Hyseq Inc			ARTHUR, LISA BENNETT	
670 Almanor A				
Sunnyvale, CA	9 <del>4</del> 003		ART UNIT	PAPER NUMBER
			1634	
			DATE MAILED: 03/22/2002	ረነ

Please find below and/or attached an Office communication concerning this application or proceeding.

,		A U. Aleman	Amplicant(a)				
•		Application No.	Applicant(s)				
		09/665,363	TANG ET AL.				
Office Action Summary		Examiner	Art Unit				
		Lisa B. Arthur	1655				
The MAILING L Period for Reply	OATE of this communication	appears on the cover sheet w	ith the correspondence address				
THE MAILING DATE  - Extensions of time may be a after SIX (6) MONTHS from  - If the period for reply specification of the period for reply is specification.	OF THIS COMMUNICATIOn vailable under the provisions of 37 CFF the mailing date of this communication ed above is less than thirty (30) days, a cified above, the maximum statutory per the rextended period for reply will, by stiffice later than three months after the maximum.	R 1.136(a). In no event, however, may a reply within the statutory minimum of thir	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
1) Responsive to	communication(s) filed on	<u> 21 February 2002</u> .					
2a)☐ This action is l	FINAL. 2b)⊠	This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) 10,11,20 and 21 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s)	is/are allowed.						
6)							
7) Claim(s) is/are objected to.							
8) Claim(s)	are subject to restriction ar	nd/or election requirement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
appl	ication from the Internationa	priority documents have bee al Bureau (PCT Rule 17.2(a)) a list of the certified copies no	n received in this National Stage ot received.				
			c. § 119(e) (to a provisional application).				
a) ☐ The translation of the foreign language provisional application has been received.  15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)	in is made of a sidini for doi	mone promy under de dien	<b>50</b> -2				
Notice of References Ci     Notice of Draftsperson's	Patent Drawing Review (PTO-94	3) 5) Notice of	w Summary (PTO-413) Paper No(s) If Informal Patent Application (PTO-152)				
3) Information Disclosure	Statement(s) (PTO-1449) Paper No	o(s) 6)					

- 1. This action is in response to the paper filed February 21, 2002. Claims 1-9, 12-19 and 22-28 have been canceled in response to the restriction requirement made in the previous office action. Claims 10,11,20 and 21 are pending in this application.
- 2. Applicant's election of Group 41, a polypeptide encoded by SEQ ID No 6 in Paper No. 8 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).
  - 3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 21 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 21 is indefinite over the recitatation of the phrase "wherein the polypeptide is provided on an array" because this phrase makes the claims unclear as to whether the claim is drawn to a polypeptide or to an array containing the polypeptide.

4. The following is a quotation of the appropriate paragraphs of 35
U.S.C. 102 that form the basis for the rejections under this section made in this
Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 10,11,20 and 21 are rejected under 35 U.S.C. 102(b) as being anticipated by Kondo et al. (J. BIOCHEMISTRY (1999) 125(4): 818-825). Kondo et al. Teaches a polypeptide which is encoded by the nucleotide sequence of SEQ ID NO 6 (see Figure 2 and sequence alignment given in attachment A). Kondo et al. teach that these nucleotide acids encode human PMSL proteins which are homologs of bacterial MutL, a protein involved in mismatch repair (abstract). While Kondo et al. Do not teach a polynucleotide which consists of entire nucleotide sequence of SEQ ID NO 2, Kondo et al. does teach the polypeptide which is encoded by the nucleic acid of SEQ ID NO 6. SEQ ID NO 6 contains untranslated sequence (nucleotides 1-522) and two putative methionine residues as potential translation start sites, the first met at nucleotide 523 of SEQ ID NO 6 and the second met at nucleotide 586 of SEQ ID NO 6. However, Kondo et al. expressed the polypeptide encoded by a nucleic acid starting at nucleotide 563 of SEQ ID NO 6 and expressed a polypeptide whose first amino acid was the second met at nucleotide 586. As a result Kondo et al. teach a polypeptide encoded by the nucleotide sequence of SEQ ID NO 6. Although Kondo et al. do not teach a polypeptide whose first amino acid is the first met at coded by nucleotide 523, Kondo et al. still teaches the claimed polypeptide because the claims are not limited to a polypeptide starting at the first methionine. Applicant should note that The nucleotide sequence of Kondo et al. was available in 1998.

6. No claims are allowable over the prior art.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa B. Arthur whose telephone number is 308-3988. The examiner can normally be reached on Monday-Wednesday from 7:00 AM to 2:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for the organization where this application or proceeding is assigned is 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-0196.

LISA B. ARTHUR
PRIMARY EXAMINEF
GROUP 1800 (600)

March 20, 2002